TABLE 2.

Demographic and clinical characteristics of post-hematopoietic cell transplant cases (with HHV-6B plasma detection) and controls (without HHV-6B plasma detection) with whole blood collected in PAXgene tubes^a

Subject	Age (yrs)	Sex	Race	Disease	Donor	HLA matchb	Engraftment dayd ,e	GVHD dayd ,f
Case 1	46	Male	Caucasian	AML	Unrelated	Mismatchedc	17
Control 1	56	Male	Hispanic	AML	Unrelated	Mismatchedc	8	47
Case 2	59	Male	Caucasian	NHL	Related	Matched	15	27
Control 2	64	Male	Caucasian	MDS	Unrelated	Matched	27	49
Case 3	54	Female	Caucasian	MM	Unrelated	Matched	21	30
Control 3	57	Female	Caucasian	NHL	Unrelated	Matched	21
Case 4	53	Female	Caucasian	MM	Related	Matched	13
Control 4	57	Female	Caucasian	MDS	Related	Matched	20
Case 5	61	Male	Caucasian	MM	Self	Matched	16
Control 5	72	Male	Caucasian	MM	Self	Matched	16
Case 6	44	Male	Caucasian	HD	Unrelated	Matched	12	28
Case 7	54	Female	Caucasian	AML	Unrelated	Mismatchedc	20	39

^aHLA, human leukocyte antigen; GVHD, graft-versus-host disease; AML, acute myelogenous leukemia; NHL, non-Hodgkin’s lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; HD, Hodgkin’s disease.

^b“Matched” indicates 10/10 allele or antigen matching.

^cUmbilical cord blood was used as the source of donor cells.

^dNumber of days post-HCT.

^eEngraftment was defined as the first of three consecutive days of an absolute neutrophil count of >500 cells/µl.

^fGVHD was defined as previously described in reference 37.